Data on immunogenicity and reactogenicity to COVID-19 vaccination among patients receiving maintenance dialysisData article Published on 2022-06-012022-10-05 Journal: Sensors (Basel, Switzerland) [Category] 변종, [키워드] acute respiratory syndrome assays cellular Cellular immune response Complete coronavirus coronavirus disease COVID-19 COVID-19 vaccination dialysis dose Effectiveness ELISPOT exclusion General population Hemodialysis homologous humoral immune response immune response Immunity immunoassay immunoglobulins increased risk interferon-γ Microparticle morbidity and mortality Patient Peritoneal dialysis produced reactogenicity receiving regimen SARS-CoV-2 SARS-CoV-2 vaccination SARS-CoV-2 vaccine single dose T cells tested the vaccine trials vaccination [DOI] 10.1016/j.dib.2022.108271 [Article Type] Data article
Reactogenicity among health care workers following a BNT162b2 or mRNA-1273 second dose after priming with a ChAdOx1 nCOV-19 vaccineObservational Study Published on 2022-06-012023-07-08 Journal: Clinical microbiology and infection : the official [Category] COVID19(2023년), [키워드] COVID-19 immunization pharmacovigilance reactogenicity Vaccine [DOI] 10.1016/j.cmi.2022.02.010 [Article Type] Observational Study
Heterologous ChAdOx1/BNT162b2 vaccination induces stronger immune response than homologous ChAdOx1 vaccination: The pragmatic, multi-center, three-arm, partially randomized HEVACC trial이종 ChAdOx1/BNT162b2 예방 접종은 동종 ChAdOx1 예방 접종보다 더 강한 면역 반응을 유도합니다. 실용적인, 다기관, 3군, 부분 무작위 HEVACC 시험Randomized Controlled Trial Published on 2022-06-012022-09-11 Journal: EBioMedicine [Category] COVID19(2023년), MERS, SARS, 변종, 비임상, 임상, 진단, [키워드] 1:1 adaptive antibody Antibody titer Antibody titers approved Arm AstraZeneca B.1.617.2 BNT BNT162b2 breath ChAdOx1 comparable conducted COVID-19 COVID-19 vaccine Delta effective first dose Frequency group groups Heterologous Heterologous COVID-19 vaccination homologous immune response immunized immunogenicity induce interim analysis less median mRNA vaccine mRNA vaccines Neutralizing antibodies Neutralizing antibody titer neutralizing antibody titers NIAID participant Pfizer Pfizer/BioNTech Pragmatic primary endpoint Randomized reactogenicity regimen response SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 variants severe adverse events spike-specific T cell statistically significant stratified by sex supported T cell T cell responses T cells Trial university vaccination vaccination schedule Vaccine vaccinees Vaccines [DOI] 10.1016/j.ebiom.2022.104073 PMC 바로가기 [Article Type] Randomized Controlled Trial
Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safeObservational Study Published on 2022-06-012022-10-05 Journal: The Lancet. Infectious Diseases [Category] Fulltext, MERS, 임상, [키워드] activities Administered Adverse adverse event analysed calculated Care center collected Control COVID-19 COVID-19 vaccination COVID-19 vaccination programme COVID-19 vaccine death deaths dose fatigue headache Health Impact initial less Local Mild moderate mRNA mRNA vaccine mRNA-based COVID-19 vaccine occurred over Pain participant prevention processed reaction reactogenicity reported Reporting Safety seeking severity study period surveillance data System systemic reactogenicity USA vaccination [DOI] 10.1016/S1473-3099(22)00054-8 PMC 바로가기 [Article Type] Observational Study
Reactogenicity after heterologous and homologous COVID-19 prime-boost vaccination regimens: descriptive interim results of a comparative observational cohort studyObservational Study Published on 2022-05-312022-10-05 Journal: BMC Infectious Diseases [Category] Coronavirus, 임상, [키워드] adjusted Adverse Adverse drug reaction age age and sex AstraZeneca BNT162b2 boost ChAdOx1 Cohort comparable Complete COVID-19 dose Efficacy Factor Frequency Gender Health Heterologous homologous immunization individual Moderna mRNA vaccine mRNA-1273 mRNA-vaccine mRNA-vaccines Observational cohort study observational study pandemic participant problem proportion reaction reactogenicity regimen regimens reported resource survey vaccination Vaccines were assessed with COVID-19 [DOI] 10.1186/s12879-022-07443-x PMC 바로가기 [Article Type] Observational Study
Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVacCoronaVac을 투여받은 성인에서 피내 경로를 통한 AZD1222의 추가 투여 후 면역원성 및 반응성Article Published on 2022-05-262022-09-11 Journal: Vaccine [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] 95%CI administration anti-S anti-SARS-CoV-2 IgG Anti-spike antibody Antibody Response Antibody responses Antibody titer AstraZeneca AZD1222 Blister booster booster dose ChAdOx1 ChAdOx1 nCoV-19 ChAdOx1 nCoV-19 vaccine cohort study common completion CoronaVac CoronaVac vaccine COVID-19 vaccine COVID-19 vaccines delta variant determine dose Endpoint Erythema evaluated geometric geometric mean geometric mean ratios GMRs healthy IgG immunogenicity Immunoglobulin Immunoglobulin G immunologic response injection Intradermal Local median age neutralization test Neutralizing antibodies neutralizing antibody Neutralizing antibody titer occurred participant participated primary endpoint proportion prospective cohort study RBD IgG reactogenicity recipient reported resource SARS-CoV-2 vaccine surrogate virus neutralization test sVNT systemic reactogenicity variant Viral Virus neutralization was collected wild type [DOI] 10.1016/j.vaccine.2022.04.067 PMC 바로가기 [Article Type] Article
Distinct immune cell dynamics correlate with the immunogenicity and reactogenicity of SARS-CoV-2 mRNA vaccine뚜렷한 면역 세포 역학은 SARS-CoV-2 mRNA 백신의 면역원성 및 반응성과 상관관계가 있습니다.Article Published on 2022-05-172022-09-12 Journal: Cell Reports Medicine [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] acute respiratory syndrome adverse event adverse events antibody AXL BNT162b2 mRNA vaccine CD11c CD16 CD56 Cell cell dynamics chemokine receptors CCR2 chemokines coronavirus CXCR3 dendritic cell dose elicit expressed expression identify immune Immune cell immune correlates immune profiling Innate immunity interferon gamma mRNA mRNA vaccine natural killer Neutralizing antibodies neutralizing antibody Neutralizing-antibody Neutralizing-antibody titers NK cells Non-classical monocytes Pfizer/BioNTech reactogenicity robust SARS-CoV-2 severity subset Vaccine vaccinees [DOI] 10.1016/j.xcrm.2022.100631 PMC 바로가기 [Article Type] Article
Immunogenicity and safety of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine: a systematic review아데노바이러스 벡터화 및 mRNA COVID-19 백신을 사용한 이종 대 상동 프라임-부스트 일정의 면역원성 및 안전성: 체계적인 검토Review Published on 2022-05-132022-09-12 Journal: Infectious Diseases of Poverty [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] Analysis Anti-spike BNT ChAdOx1 nCoV-19 comparable coronavirus disease COVID-19 COVID-19 vaccines database Evidence Heterologous heterologous prime-boost heterologous vaccination higher risk homologous Homologous vaccination immunogenicity Local local reaction Messenger RNA Meta-analysis mRNA mRNA-1273 neutralizing antibody Participants Protein reactogenicity risk Safety searched serum antibody spike-specific T cell supported systematic review systemic reaction T cell vaccination Vaccine Web of Science [DOI] 10.1186/s40249-022-00977-x PMC 바로가기 [Article Type] Review
Humoral Immune Response Diversity to Different COVID-19 Vaccines: Implications for the “Green Pass” Policy다양한 COVID-19 백신에 대한 체액 면역 반응 다양성: "그린 패스" 정책에 대한 시사점Article Published on 2022-05-112022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, [키워드] ACE2 binding activities Ad26 Ad26.COV2.S age Analysis anti-RBD anti-RBD antibody titer antibody Antibody Response Antibody titer appear assumption average binding BNT162b2 booster vaccination ChAdOx1 ChAdOx1 nCoV-19 ChAdOx1 nCoV-19 vaccine ChAdOx1 nCoV-19 vaccines concentrations country COV2.S COVID-19 COVID-19 infection COVID-19 pandemic detect Diversity elicit elicited eligibility epitope evaluated Features green Green Pass Policy heterogeneous humoral humoral immune response immune Immunity implication individual maintain mRNA mRNA-1273 Neutralizing Neutralizing activity Neutralizing antibodies neutralizing antibody observé Pass peptides Policy Protein Randomly Rapid test rationale RBD RBD-ACE2 reactivity reactogenicity Receptor-binding domain reduce reopening response Safe SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 spike selected sera serum serum sample significantly spike Spike protein synthetic peptide the receptor-binding domain titer vaccinated individual vaccination Vaccine virus spread [DOI] 10.3389/fimmu.2022.833085 PMC 바로가기 [Article Type] Article
Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study건강한 성인에서 AS03 보조제 SARS-CoV-2 재조합 단백질 백신(CoV2 preS dTM)의 안전성 및 면역원성: 2상, 무작위, 용량 찾기, 다기관 연구의 중간 결과Clinical Trial Published on 2022-05-012022-09-11 Journal: The Lancet. Infectious Diseases [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, [키워드] 95% CI abstinence adjuvants Adults adverse event adverse events Adverse reaction Adverse reactions age All participant All participants antibody Antibody titre Antigen AS03 assessments assigned authority baseline booster vaccination candidate vaccine Chemotherapy childbearing potential clinical development Clinical research clinical trial Cohort Contraception COVID-19 vaccine D614G variant development dose effective Endpoint enrolled evaluated expected fixed Frequency geometric mean geometric mean titre GMT GMT ratio GMTs groups healthy High dose High-dose high-dose group Immunocompromised immunogenicity increase in increased risk injection injection site Injections intensity interim results investigator investigators involved Laboratory lactating low dose low-dose medical condition Medical conditions medium medium dose Mild mild to moderate moderate multicentre Neutralising Antibodies neutralising antibody neutralising antibody titre neutralising antibody titres occurred Older Older adults Organ transplant outcome outcome assessor outcome assessors parallel-group participant Participants Phase 2 Phase 3 positive prefusion pregnant primary immunogenicity progression proportion Protein protocol provided pseudovirus neutralisation assay randomised Randomly reactogenicity receive Registered reported Research research and development responses robust Safety safety analysis safety endpoints safety profile Sanofi Pasteur SARS-CoV-2 second dose second vaccination selected Serious Adverse Event Serious Adverse Events serodiagnostic Seven severe COVID-19 Stratification study period supported systemic test result titre titres Treatment treatment group treatment groups Trial USA vaccination Vaccine was done were excluded were measured yes or no [DOI] 10.1016/S1473-3099(21)00764-7 PMC 바로가기 [Article Type] Clinical Trial